Skip to main content

Month: August 2020

EfTEN Real Estate Fund III AS ostis 11,8 miljoni euroga büroohoone Vilniuses

EfTEN Real Estate Fund III AS-i tütarettevõte Rutkausko UAB ostis Vilniuses asuva büroohoone, mille ankurrentnik on rahvusvaheline IT-firma Atea. Tehing viidi lõpule reedel, 14. augustil 2020.Tehingu maksumus on 11,8 miljonit eurot, millest 4,5 miljonit eurot finantseeritakse EfTEN Real Estate Fund III AS-i investeerimata kapitaliga ning 7,3 miljonit eurot SEB Panga laenuga, mille marginaal on 2,1 protsenti. Keskmine puhastootlus projekti sisenemisel on 7,1 protsenti. Büroohoone müüb Sonex Consulting UAB ning käesoleva tehinguga saab fondi kogu kapital täielikult investeeritud. ”Ajal, kus tehingud kommertskinnisvaraga pole tavalised, otsustasime ujuda vastuvoolu ning laiendada EfTEN Real Estate Fund III AS-i portfelli kaasaegse ning tugeva ankurrentnikuga büroohoonega Vilniuses. Olles hoolikalt kaardistanud Baltimaade ärikinnisvara turgu,...

Continue reading

FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)

First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeksFirst and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technologyApproval supported by one of the largest clinical trial programmes undertaken for this rare diseaseBasel, 17 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved ENSPRYNG™ (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, lifelong and debilitating autoimmune disorder of the central nervous...

Continue reading

Kiadis collaborates with premier Dutch institutions to apply K-NK-cell technology for the development of a novel COVID-19 therapy

Initiates new COVID-19 research and development program (K-NK-ID101)Expands the application of Kiadis’ K-NK technology into infectious diseasesAnnounces collaboration with five premier Dutch institutions: Viroclinics-DDL; Harbour BioMed Netherlands; Sanquin Bloedvoorziening; Erasmus Medical Center; and the Utrecht University, each contributing a unique strength in virology and COVID-19 research and know howSubmitted grant application with US governmentAmsterdam, The Netherlands, August 17, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell-based medicines for life-threatening diseases, announces a new research program, K-NK-ID101, that will focus on the development of K-NK cells as a treatment for COVID-19. This new program...

Continue reading

Half-year results for 2020: earnings growth despite tough market conditions

Steinhausen, August 17, 2020 – Schweiter Technologies reported a strong first half in 2020 despite challenging market conditions. Group revenues declined by -9% versus the same period the previous year to CHF 559.5 million, owing to the COVID-19 pandemic and negative currency effects. The decline in local currencies was -4%. In contrast, EBITDA rose by +10% to CHF 67.9 million (up +16% in local currencies). The return on net sales improved to 12.1%. Operating profit (EBIT) rose by 14% to CHF 49.3 million (+20% in local currencies), while net income grew to CHF 35.3 million. Operating cash flow expanded by +64% to CHF 56.5 million. Cash and cash equivalents stand at CHF 114.4 million following a dividend distribution of approximately CHF 57 million.The diversification of 3A Composites proved to be a strength in the first half-year, which...

Continue reading

Halbjahresergebnis 2020: Ergebniswachstum in schwierigem Markt-umfeld

Steinhausen, 17. August 2020 – Schweiter Technologies verzeichnete in einem herausfordernden Marktumfeld ein gutes 1. Halbjahr 2020. Der Gruppenumsatz reduzierte sich beeinträchtigt durch die COVID-19 Pandemie und negativen Währungseinflüssen im Vergleich zur Vorjahresperiode um -9% auf CHF 559.5 Mio. (-4% in lokalen Währungen). Im Gegensatz dazu erhöhte sich der EBITDA um +10% auf CHF 67.9 Mio. (+16% in lokalen Währungen). Die Rentabilität zum Nettoumsatz verbesserte sich auf 12.1%. Das Betriebsergebnis (EBIT) erhöhte sich um 14% auf CHF 49.3 Mio. (+20% in lokalen Währungen) und der Reingewinn auf CHF 35.3 Mio. Der operative Cashflow legte um +64% auf CHF 56.5  Mio. zu. Die liquiden Mittel betragen CHF 114.4 Mio. nach einer Dividendenausschüttung von rund CHF 57 Mio.In einem von der COVID-19 Pandemie geprägten ersten Halbjahr stellte...

Continue reading

RAK Petroleum plc Releases Half-Year Financial Report for the Period Ended 30 June 2020

United Kingdom, 17 August 2020RAK Petroleum plc, the Oslo-listed oil and gas investment company, today released its Half-Year Financial Report for the period ended 30 June 2020.  A copy is attached and is available at http://www.rakpetroleum.uk/Investor-relations/Reports-and-presentations/Financial-reporting/Annual-reports.*****************For further queries, please contact:Kevin TonerManaging DirectorRAK Petroleum plcEmail: kevin.toner@rakpetroleum.ukAbout RAK Petroleum plcRAK Petroleum plc is an Oslo Stock Exchange listed oil and gas investment company established under the laws of England and Wales as a public limited company. Its principal holdings are 44.94 percent of DNO ASA and 33.33 percent of Foxtrot International LDC held through Mondoil Enterprises, LLC. DNO ASA is a Norwegian oil and gas operator focused on the Middle East...

Continue reading

Heimavellir hf. – Innlausnarferli

Fredensborg ICE ehf. hefur ákveðið að nýta sér innlausnarrétt skv. 110. gr. l. nr. 108/2007 í tengslum við hlutabréf Heimavalla hf. Innlausnarferlið hefst mánudaginn 17. ágúst 2020 og lýkur mánudaginn 14. september 2020.Frekari upplýsingar um innlausnarferlið má finna á heimasíðu Heimavalla hf., https://www.heimavellir.is/is/fredensborg-ice-ehf-1, þar er einnig að finna framsalseyðublað sem hluthafar Heimavalla hf. geta fyllt út til að framselja hluti sína til Fredensborg ICE ehf.Tilkynning um innlausnarferlið verður einnig birt í Morgunblaðinu mánudaginn 17. ágúst 2020.Frekari upplýsingar veitir fjárfestatengill Heimavalla hf.,Erlendur Kristjánsson, s:669-6940, Erlendur@heimavellir.is

Continue reading

Unibail-Rodamco-Westfield (“URW”) responds to market rumours

 Paris, Amsterdam, August 16, 2020Press releaseUnibail-Rodamco-Westfield (“URW”) responds to market rumoursURW refers to recent market rumours in relation to a potential rights issue.As detailed in its H1-2020 results communication, as at June 30, 2020, URW had €12.7 Bn of cash and undrawn credit facilities at its disposal. URW has taken a number of steps in response to the COVID-19 pandemic to strengthen its liquidity and balance sheet, including the cancellation of the second dividend instalment, deferring non-essential capital expenditures, a further reduction of the development pipeline and the completion of the disposal of five French shopping centres.As previously communicated, deleveraging is a priority for URW, starting with asset disposals as evidenced by its intention to sell €4 Bn of assets in the next couple of years, on top...

Continue reading

Constellation Software Inc. Announces Changes to its Management Team

TORONTO, Aug. 16, 2020 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced the resignation of John Billowits, Chief Executive Officer (CEO) of the Vela Operating Group (“Vela”) and the appointment of Damian McKay as his replacement, with effect from September 30, 2020.  John Billowits will continue to act as a director to Constellation and will assist in the transition over the next twelve months and beyond as required. Damian McKay has been with Constellation for five years as CEO of DMG, an operating group within Vela. Prior to joining Constellation, Damian served as CEO of Datamine and in various executive positions with General Electric in Australia.Mark Leonard, said, in commenting upon the announcement: “We owe John a debt of thanks.  John oversaw the development of Vela...

Continue reading

Platinex Inc. Announces Option Issuance

TORONTO, Aug. 16, 2020 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (the “Company” or “Platinex“) would like to announce that it has granted 200,000 options to consultants effective August 14, 2020. The options are priced at the previous days close of $0.07 and expire on August 14, 2025.Lori Paradis, Assistant Secretary                               Tel: (416) 268-2682                         Email: lparadis@platinex.comWeb: www.platinex.com  About Platinex Inc. – Advancing a District Scale Project in an Abitibi Gold CampPlatinex is focusing its efforts on the exploration of its property in the Shining Tree District. Platinex with the above acquisition has created the largest combined gold focused property package in the Shining Tree District, Northern Ontario, which has received little modern exploration...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.